ST Tian Sheng released its 2026 interim report on August 25, 2026. The company's total operating revenue was 233 million yuan, net profit attributable to the parent company was a loss of 24.1731 million yuan, and net cash inflow from operating activities was 44.3636 million yuan. The company's latest asset-liability ratio was 24.69%, gross margin was 48.84%, a decrease of 0.05 percentage points from the same period last year, latest ROE was negative 1.25%, and diluted earnings per share was negative 0.08 yuan. The company's latest total asset turnover was 0.09 times, inventory turnover was 1.21 times, number of shareholders was 10,300, and the top ten shareholders held 149 million shares, accounting for 46.91% of total share capital.
Tiansheng Pharmaceutical Group Co LtdNet loss of 24.17 million yuan in interim report